Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
September 27 2023 - 10:51AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of September 2023
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Issued: 27 September 2023, London UK
GSK announces Wendy Becker to join the Board as Non-Executive
Director
GSK plc (LSE/NYSE: GSK) has today announced that Wendy Becker will
join the Board of the Company as a Non-Executive Director with
effect from 1 October 2023.
On joining the Board, Wendy will become a member of the Company's
Remuneration Committee. She will succeed Urs Rohner as Chair of the
Remuneration Committee after the Company's 2024 Annual General
Meeting when Urs steps down on completion of his nine years'
service to the Board.
Wendy is currently Chair of Logitech International S.A., and a
Board member and Chair of the Compensation Committee of Sony Group
Corporation. She has strong executive management experience
including senior roles at McKinsey & Company, TalkTalk, and
Vodafone and as CEO at Jack Wills. Within the life sciences
sector, Wendy is a Board member and Chair of the Remuneration
Committee of Oxford Nanopore Technologies plc. She is a member of
the governing bodies of the University of Oxford and related
subsidiaries.
Commenting on Wendy's appointment, Sir Jonathan Symonds, Chair of
GSK said: "I am delighted
to welcome Wendy to GSK. Wendy is a highly experienced
non-executive director, and has held significant leadership
positions in a wide range of global businesses, including several
in the technology and life sciences sectors. I'm sure she will make
a significant contribution to the Board and we look forward to her
joining in October."
Notes:
|
1.
The appointment of Wendy Becker was made by the Board on the
recommendation of the Nominations & Corporate Governance
Committee. The Committee conducted an extensive search and
selection process for this appointment, using an external search
firm, which is a signatory of the Voluntary Code of Conduct for
Executive Search Firms. The external search firm provided a diverse
list of candidates who were approached, evaluated and interviewed,
against an agreed set of criteria aligned to the Board's target
skills matrix. The Board satisfied itself that Ms Becker had
the experience and time available to carry out the
role.
|
|
2.
The Board has determined that Wendy Becker is an independent
Non-Executive Director in accordance with the UK Corporate
Governance Code.
|
|
3.
Ms Becker will receive the standard basic fee for a Non-Executive
Director of £113,800 per annum (including travel
allowance).
She
will receive fees of £40,000 per annum when she succeeds Mr
Rohner as Chair of the Remuneration Committee.
Ms
Becker will be required to build towards a share ownership
requirement of GSK shares in accordance with the Company's
shareholder approved Non-Executive remuneration
policy.
|
|
4.
Ms Becker will also become a member of the Audit & Risk
Committee on her appointment.
|
|
5.
Ms Becker does not have a service contract. She has a letter of
appointment which may be viewed by contacting the Company Secretary
at the Company's registered office.
|
|
6.
There are no further disclosures to be made in respect of Ms
Becker's appointment under Listing Rule 9.6.13R.
|
|
7. As of 1 October 2023 the Board of GSK will
comprise:
|
|
Sir
Jonathan Symonds
|
Non-Executive
Chair
|
|
Emma
Walmsley
|
Chief
Executive Officer
|
|
Julie
Brown
|
Chief
Financial Officer
|
|
Charles
Bancroft
|
Senior
Independent Non-Executive Director
|
|
Elizabeth
McKee Anderson
|
Independent
Non-Executive Director
|
|
Dr Hal
Barron
|
Non-Executive
Director
|
|
Dr Anne
Beal
|
Independent
Non-Executive Director
|
|
Wendy
Becker
|
Independent
Non-Executive Director
|
|
Dr Hal
Dietz
|
Independent
Non-Executive Director
|
|
Dr
Jesse Goodman
|
Independent
Non-Executive Director
|
|
Urs
Rohner
|
Independent
Non-Executive Director
|
|
Dr
Vishal Sikka
|
Independent
Non-Executive Director
|
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com.
GSK enquiries
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
Investor Relations:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
Camilla Campbell
|
+44 (0) 7803 050238
|
(London)
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Risk factors" in the company's Annual Report on Form 20-F for
2022, and Q2 Results for 2023 and any impacts of the COVID-19
pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlese
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GSK plc
|
|
(Registrant)
|
|
|
Date: September
27, 2023
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From May 2024 to Jun 2024
GSK (PK) (USOTC:GLAXF)
Historical Stock Chart
From Jun 2023 to Jun 2024